(NYSE: NUVB) Nuvation Bio's forecast annual revenue growth rate of 120.1% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 99.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.58%.
Nuvation Bio's revenue in 2025 is $26,748,000.On average, 12 Wall Street analysts forecast NUVB's revenue for 2025 to be $19,151,704,068, with the lowest NUVB revenue forecast at $11,896,320,125, and the highest NUVB revenue forecast at $25,486,237,409. On average, 12 Wall Street analysts forecast NUVB's revenue for 2026 to be $57,054,339,920, with the lowest NUVB revenue forecast at $35,760,955,396, and the highest NUVB revenue forecast at $74,768,543,403.
In 2027, NUVB is forecast to generate $98,451,476,955 in revenue, with the lowest revenue forecast at $62,189,984,746 and the highest revenue forecast at $129,248,204,241.